Biocartis Group NV Stock price

Equities

BCART

BE0974281132

Medical Equipment, Supplies & Distribution

Real-time Euronext Bruxelles 11:35:06 2023-09-22 am EDT 5-day change 1st Jan Change
0.29 EUR +1.05% Intraday chart for Biocartis Group NV -.--% -.--%
Sales 2023 * 58.4M 62.91M Sales 2024 * 76.3M 82.19M Capitalization 27.24M 29.34M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * 0.47 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 0.36 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 526
Yield 2023 *
-
Yield 2024 *
-
Free-Float 93.41%
More Fundamentals * Assessed data
Dynamic Chart
Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress CI
Biocartis, APIS Assay Technologies to Commercialize Estrogen Receptor-positive Mutations Kit MT
Biocartis Group NV Announces Expansion of Its Collaboration with APIS Assay Technologies Ltd to Commercialize the APIS ESR1 Mutations Kit CI
Biocartis Winding Down Begins with Creditors' Takeover of Operating Units MT
Biocartis Group NV Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Biocartis Appoints New Medical Advisory Board of Renowned Practice Leaders CI
Biocartis, Eli Lilly to Develop Diagnostics System to Identify Therapy-eligible Lung Cancer Patients MT
Biocartis Group NV Partners with Lilly to Explore Biomarker Testing for NSCLC Patients Using the Idylla? Platform CI
Molecular Diagnostics Company Biocartis Group Names New CFO MT
Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023 CI
Biocartis Group NV Appoints George Cardoza as Head of Service Delivery, Effective 7 August 2023 CI
Biocartis CFO to Depart in August MT
Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO CI
Certain ordinary shares of Biocartis Group NV are subject to a Lock-Up Agreement Ending on 2-JUN-2023. CI
Biocartis, HiloProbe Enter Commercialization Partnership for Colorectal Cancer Test MT
More news
1 week
0.29
Extreme 0.287
0.29
1 month
0.29
Extreme 0.287
0.29
Current year
0.29
Extreme 0.287
0.29
1 year
0.29
Extreme 0.285
0.79
3 years
0.29
Extreme 0.285
4.80
5 years
0.29
Extreme 0.285
12.50
10 years
0.29
Extreme 0.285
15.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 23-04-23
Chairman 51 17-08-30
Director of Finance/CFO 62 23-08-06
Members of the board TitleAgeSince
Chief Executive Officer 56 23-04-23
Director/Board Member 70 18-05-10
Director/Board Member 71 18-05-10
More insiders
Date Price Change Volume
24-03-28 0.29 -.--% 0
24-03-27 0.29 -.--% 0
24-03-26 0.29 -.--% 0
24-03-25 0.29 -.--% 0
24-03-22 0.29 -.--% 0

Real-time Euronext Bruxelles, September 22, 2023 at 11:35 am EDT

More quotes
Biocartis Group NV specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes. Net sales by source of income are mainly distributed between products sales (78.3%) and sale of collaboration services (19.3%; especially research and development services).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.29 EUR
Average target price
1.1 EUR
Spread / Average Target
+279.31%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Biocartis Group NV - Euronext Bruxelles